Vial (@VialTrials) header
Vial (@VialTrials) profile picture

Next-generation pharma company. Focused on advancing a pipeline of potentially best-in-class biologics and RNA therapeutics across areas of unmet need.

San Francisco, CA
Joined April 2022
Photo by Vial (@VialTrials)Photo by Vial (@VialTrials)Photo by Vial (@VialTrials)Photo by Vial (@VialTrials)Photo by Vial (@VialTrials)Photo by Vial (@VialTrials)Photo by Vial (@VialTrials)Photo by Vial (@VialTrials)Photo by Vial (@VialTrials)Photo by Vial (@VialTrials)
Vial has dosed the first patient with asthma in the Phase 1b study of Vial's IL-13 x TSLP bispecific antibody. Following a positive Phase 1a, Vial's IL-13 x TSLP takes its ultra-long-acting profile into patients, with potential across asthma and other inflammatory diseases.
1
1
4
446
Despite their effects, GLP‑1-based therapies fall short for many patients. Dr. Samuel Klein MD, the Director for the Center of Human Nutrition at WashU noted that patients on GLP-1s experience very heterogenous response, including uneven weight-loss, intolerable side effects, and high dropout rates. This suggests an urgent need for a more targeted and more sustainable treatment for obesity, like Vial’s INHBE siRNA program, which was designed to have a more targeted MoA and higher tolerability to mitigate discontinuation. Discover Vial’s INHBE program: bit.ly/4nshGSQ
2
295
The benefits of GLP‑1s are often overshadowed by their side effects, with many patients discontinuing treatment within the first year. According to Dr. Tim Garvey MD, of UAB, obesity is a lifelong disease, and patients need more tolerable and sustainable options. Vial’s INHBE siRNA is the perfect solution, as the therapeutic is designed to be more targeted, more tolerable, and focused on reducing adiposity to enable quality weight loss rather than simply restricting calories. Discover Vial’s INHBE program: bit.ly/4nshGSQ
2
226
GLP‑1s have transformed obesity care, but they are not right for everyone. Obesity expert and researcher Dr. Lawrence Cheskin MD outlines which patients could benefit from Vial’s INHBE siRNA program, a novel target designed to drive meaningful weight loss and support long‑term health. Discover Vial’s INHBE program: bit.ly/4nshGSQ
2
200
As obesity treatments advance, it’s crucial to address unmet needs of specific patient populations. Dr. Jens Juul Holst from the University of Copenhagen highlights why preserving muscle in older adults is key, especially as age-related injuries and falls remain major risks. Unlike GLP-1s, Vial’s INHBE siRNA program targets fat specifically, sparing lean muscle and enabling both generalized and population-tailored weight loss. Discover Vial's INHBE program: bit.ly/4nshGSQ
2
138
Vial is geared up to attend the 44th Annual J.P. Morgan Healthcare Conference in San Francisco next week! Reach out to us — we’d love to meet. See you all there!
1
1
113
The prevalence of comorbidity in patients with obesity is high, which can have severe health implications. Nephrologist and best-selling author of The Obesity Code, @drjasonfung believes that targeting fat distribution via INHBE is beneficial for overall metabolic health. This highlights Vial’s INHBE siRNA program as a promising therapeutic approach to not only improve the quality of fat loss but also address the overall distribution of fat. Discover Vial’s INHBE program: bit.ly/4nshGSQ
1
1
121
GI intolerance of GLP-1s is a major problem for those currently on the obesity treatment. Dr. Lee Kaplan MD, Director of @DartmouthHealth's Weight and Wellness Center, suggests new MoAs to tackle this issue and highlights Vial’s INHBE siRNA program as a promising target to compliment and potentially enhance current treatments. Discover Vial’s INHBE program: bit.ly/4nshGSQ
1
116
While patients on GLP-1s lose weight, the drug does not target the underlying cause for obesity - adipose tissue. Here, Dr. @DrSharma, Professor Emeritus at the @UAlberta, emphasizes how Vial’s INHBE siRNA directly impacts the function of adipose tissue to better address cellular hypertrophy and inflammation. Discover Vial’s INHBE program: bit.ly/4nshGSQ
2
102
As obesity treatments move beyond “weight loss at any cost,” there’s a growing need for therapies that improve body composition, including preserving lean muscle mass. Dr. Daniel Bessesen, MD, a renowned endocrinologist and Director of the Health and Wellness Center at @CUAnschutz, discusses the mechanism of VIAL-INHBE and how it overcomes these challenges. Discover Vial’s INHBE program: bit.ly/4nshGSQ
2
102
There are major challenges with GLP-1s and loss of lean muscle tissue. Here, Dr. Robert Eckel MD (@RobertEckel12), Professor of Medicine at @CUAnschutz stresses how Vial’s INHBE program tackles this challenge by enabling quality weight loss that preserve lean muscle mass. Discover Vial’s INHBE program: bit.ly/4nshGSQ
1
2
123
Obesity expert and researcher, Dr. Lawrence Cheskin MD, discusses how targeting adipose tissue is critical for treating obesity, positioning INHBE as a promising target to drive quality fat loss. Discover Vial's INHBE program: bit.ly/4nshGSQ
1
1
1
415
Dr. Scott Kahan (@scottkahan) Director of the National Center for Weight and Wellness at Johns Hopkins Bloomberg School of Public Health, highlights the importance of new mechanisms of action beyond GLP-1 therapies.
2
2
162
These innovative approaches - targeting muscle, fat, and liver cells - could help people who currently don’t respond to or can’t tolerate existing medications. Read more about Vial's INHBE siRNA program for obesity and cardiomet indications at: vial.com/inhbe-activin-e/
117
Dr. Lee Kaplan, Director of the Weight and Wellness Center at Dartmouth Health and Director at the Obesity and Metabolism Institute, highlights the potential of the INHBE-myostatin/activin pathway in obesity treatment.
1
128
Read more about Vial's INHBE siRNA program at: vial.com/inhbe-activin-e/
73
It’s clear the next breakthrough in obesity treatment will come from entirely new mechanisms that go beyond appetite suppression like VIAL-INHBE. Hear more from Dr. Jens Juul Holst, Professor at the Department of Biomedical Sciences and Senior Group Leader at Novo Nordisk Foundation Center for Basic Metabolic Research.
1
141